Home / Legislation / Govt grant to help develop breast cancer tests

Govt grant to help develop breast cancer tests

Research on a blood test for the detection and monitoring of breast cancer has taken a step forward with the Federal Government announcing a $372,654 grant.
Legislation

Research on a blood test for the detection and monitoring of breast cancer has taken a step forward with the Federal Government announcing a $372,654 grant to the medical diagnostics company BARD1 Life Sciences (ASX: BD1).

The grant, announced by the Minister for Health, Greg Hunt, will be used to develop, clinically evaluate and commercialise liquid biopsy tests to detect and monitor breast cancer using BARD1’s proprietary SubB2M cancer-specific probe.

Breast cancer remains the biggest cause of cancer-related death for women, with an estimated 2.8 million new cases and 626,679 deaths worldwide in 2018. In Australia, there was an estimated 19,371 women diagnosed with breast cancer and 3058 deaths in 2019.

  • BARD1 CEO, Dr Leearne Hinch, said: “This funding, which will be matched by BARD1, reflects the importance and commercial potential of our SubB2M-based liquid biopsy tests (essentially blood tests) to detect and monitor breast cancer.

    “The SubB2M molecule binds to a cancer-specific sugar molecule that is only found on human cancer cells, potentially enabling the development of highly-specific blood tests with low false positives, radically improving how breast cancer is detected and monitored.

    “Giving women access to non-invasive, accurate and reliable blood tests to detect and monitor breast cancer could greatly improve their health outcomes by providing earlier detection, informing treatment decisions and improving long-term survival.”

    “With the support of the BTB program, BARD1 plans to develop and commercialise SubB2M-based liquid biopsy tests for monitoring patients already diagnosed with breast cancer for treatment response and recurrence, and as an adjunct to screening mammography.”

    The government funding will allow BARD1 to build on previous data generated by the University of Adelaide and Griffith University to advance the development of a simple. non-invasive breast cancer test to detect and monitor breast cancer.

    The current project will be performed collaboratively by BARD1, the Institute for Glycomics at Griffith University and the Paton Laboratory at the University of Adelaide over 22 months.

    BARD1 Chief Scientific Officer, Dr Peter French, said: “SubB2M is potentially one of the most exciting breakthroughs in cancer diagnostics that I have seen in 40 years of medical research.”


    Related
    Higher inflation, recession more likely: Franklin Templeton

    Late July news of the Federal Reserve (Fed) increasing interest rates another 0.75% and a second negative quarter of economic growth (GDP) has created an uncertain environment for investors going forward. Adding to these concerns is China’s economic slowdown and Europe’s energy shock.  Stephen Dover, Chief Market Strategist, at the Franklin Templeton Investment Institute presents…

    Stephen Dover | 15th Aug 2022 | More
    Jones looks to shorten exam, improve ethics code

    Once the advice review is completed, the minister has asked Treasury to look at updating the ethics code and assessing the viability of a shortened adviser exam.

    Tahn Sharpe | 15th Aug 2022 | More
    AZ NGA dives into supply chain with Virtual Business Partners tie-up

    The Italian-backed group has teamed up with one of AMP’s largest advice businesses to take a major stake in the back-office services provider. It’s the first time AZ NGA has ventured beyond advice and accounting investment.

    Tahn Sharpe | 15th Aug 2022 | More
    Popular
    1
    Advisers urged to tread carefully with ‘wholesale investor’ status
    Staff Writer | 28th Jul 2022 | More
    2
    Top hedge fund award goes to L1 Capital
    Greg Bright | 13th Dec 2021 | More
    3
    MAX Award winners and the new world outside
    Greg Bright | 13th Jun 2022 | More
    4
    INDepth with Andrew Lockhart from Metrics Credit Partners
    The Inside Adviser | 30th Jun 2022 | More